International prevalence of consultation with a naturopathic practitioner: a systematic review and meta-analysis

Amie Steel, Rebecca Redmond, Janet Schloss, Holger Cramer, Joshua Goldenberg, Matthew J Leach, Joanna Elizabeth Harnett, Claudine Van de Venter, Andy McLintock, Ryan Bradley, Jason Hawrelak, Kieran Cooley, Brenda Leung, Jon Adams, Jon Wardle

ABSTRACT

Objectives Naturopathy is a traditional medicine system informed by codified philosophies and principles, and an emphasis on non-pharmacologic therapeutic interventions. While naturopathy is practised by approximately 75 000–100 000 000 naturopathic practitioners in at least 98 countries, little is known about the international prevalence of history of consultation with a naturopathic practitioner. This study reports a systematic review and meta-analysis of studies describing the global prevalence of history of consultation with a naturopathic practitioner by the general population.

Setting The included literature was identified through a systematic search of eight databases between September and October 2019, as well as the grey literature.

Participants Studies were included if they reported the prevalence rate of consultations with a naturopathic practitioner by the general population.

Interventions Survey items needed to report consultations with a naturopathic practitioner as defined in the country where data was collected, and not combine naturopathic consultations with other health services or only report consultations for illness populations.

Primary and secondary outcome measures Primary measures used for the analysis was consultations in the country where data was collected, and not combine naturopathic consultations with other health services or only report consultations for illness populations.

Methods Meta-analysis of prevalence data was conducted using random effects models based on individual countries and WHO world regions.

Results The literature search identified eight manuscripts summarising 14 studies reporting prevalence for inclusion in the review. All included studies had a low risk of bias. Meta-analysis of the included studies by world region found the 12-month prevalence of history of naturopathy consultations ranged from 1% in the Region of the Americas to 6% in the European and Western Pacific Regions.

Conclusions There are up to sixfold differences in the prevalence of naturopathy consults over 12 months between and within world regions, which may be driven by a range of policy, legislative and social factors.

PROSPERO registration number CRD42020145529.

INTRODUCTION

Naturopathy is a traditional medicine system underpinned by six philosophical principles (see box 1), which were codified by the profession in the 20th century. These philosophical principles characterise naturopathic practice and are globally accepted by the profession. Other defining tenets of naturopathy are patient-centredness and individualisation, with naturopaths typically drawing on a range of therapeutic interventions (eg, diet and lifestyle counselling, herbal medicine, nutritional supplementation, manual therapies and mind–body practices) to best meet the healthcare needs and preferences of the patient. Globally, naturopathy is practised in at least 98 countries with representation in every world region. Naturopathy is practised widely in Europe (n=54 practicing countries), followed by Latin America (n=51), Africa (n=47) and the Western Pacific (n=37). Estimates from the World Naturopathy Federation suggest there are between 75 000 and 100 000 naturopaths currently in clinical practice across the world.
Training of the naturopathic workforce is currently provided by an estimated 90 education institutions globally, with entry-level qualifications ranging from technical diploma to clinical doctorate. The curriculum of these naturopathic programmes typically includes content in health sciences (eg, anatomy, physiology, chemistry and biochemistry), clinical sciences (eg, clinical examination, differential diagnosis), social sciences (eg, psychology, counselling) and naturopathic sciences (eg, nutritional medicine, herbal medicine, lifestyle medicine, dietary modification, homeopathy and manual therapies). Despite similarities in the content of these training programmes, naturopathic scope of practice varies considerably across jurisdictions due to differences in regulation and legislative requirements ranging from voluntary certification, coregulation, negative

<table>
<thead>
<tr>
<th>WHO region</th>
<th>No occupational regulation, licensure or registration identified</th>
<th>Voluntary certification</th>
<th>Type of occupational regulation</th>
<th>Statutory registration/occupational licensing</th>
</tr>
</thead>
<tbody>
<tr>
<td>African Region</td>
<td>Angola, Kenya, Mauritius Zamb</td>
<td>None identified</td>
<td>Coregulation</td>
<td>Botswana, Democratic Republic of the Congo, Ghana, Namibia, Nigeria, South Africa, Swaziland, Tanzania, Uganda, Zimbabwe</td>
</tr>
<tr>
<td>Region of the Americas</td>
<td>Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, British Virgin Islands, Costa Rica, Dominica Republic, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Saint Martin, Trinidad and Tobago, Venezuela, Virgin Islands</td>
<td>Bermud, Brazil, Canada*, U*SA, Uruguay</td>
<td>Brazil</td>
<td>None identified Canada, Chile, Colombia, Cuba, Ecuador, Peru, Puerto Rico, Saint Lucia, USA</td>
</tr>
<tr>
<td>Eastern Mediterranean Region</td>
<td>Bahrain, Egypt, Iran, Kuwait, Morocco, Qatar</td>
<td>None identified</td>
<td>None identified</td>
<td>Saudi Arabia, United Arab Emirates</td>
</tr>
<tr>
<td>European Region</td>
<td>Austria, Bosnia and Herzegovina, Finland, Hungary, Israel, Luxembourg, Russia, Slovakia, Ukraine</td>
<td>Belgium, Czech Republic, Denmark, France, Greece, Ireland, Italy, Norway, Netherlands, Slovenia, Spain, Sweden, UK</td>
<td>Norway, UK</td>
<td>None identified Albania, Cyprus, Germany, Iceland, Liechtenstein, Portugal, Romania, Switzerland</td>
</tr>
<tr>
<td>South-East Asia Region</td>
<td>Indonesia, Sri Lanka, Thailand</td>
<td>None identified</td>
<td>None identified</td>
<td>India, Nepal</td>
</tr>
<tr>
<td>Western Pacific Region</td>
<td>Cambodia, China, Fiji, Japan, Philippines, Republic of Korea, Singapore, Vanuatu, Vietnam</td>
<td>Australia, Hong Kong, New Zealand</td>
<td>Australia</td>
<td>Cook Islands, Malaysia, Samoa</td>
</tr>
</tbody>
</table>

*Voluntary certification regimens are present in some provinces (Canada) and States (USA) when occupational licensing or statutory registration is absent.
licensing and statutory registration/occupational licensing, as seen in table 1.\textsuperscript{6}

In response to an increase in the use of traditional and complementary medicine (including the utilisation of naturopathic health services), the WHO has developed global strategies to ensure access to safe and effective healthcare, which include promoting the integration of traditional and complementary therapies (including naturopathy) into healthcare systems.\textsuperscript{7} Several international research studies suggest the demand for naturopathic services may be attributed to personal healthcare beliefs, dissatisfaction with biomedical care, increased disease severity and unmet healthcare needs.\textsuperscript{8-15} Nevertheless, the global use of naturopathic services is not well understood. Therefore, the aim of this study was to describe the prevalence of a history of consultations with naturopathic practitioners globally, including potential differences across world regions.

**METHODS**

**Aim**

This study aims to describe the global prevalence of a history of consultation with a naturopathic practitioner by the general population.

**Study design**

A systematic review and meta-analysis of prevalence studies were undertaken in accordance with the AMSTAR 2 guidelines.\textsuperscript{16} The protocol for this review was submitted to PROSPERO on the 2 September 2019 and was registered on the 28 April 2020.

**Inclusion and exclusion criteria**

Articles were included that reported original data from cohort studies, cross-sectional studies, survey research, case–control studies, prevalence studies or epidemiological studies. Studies reporting on the general population prevalence of consultations with a naturopathic practitioner either in the previous 12 months or over the user’s lifetime were considered for inclusion. All relevant papers were included irrespective of language of publication or risk of bias score. Articles were excluded that presented results from specific subpatient populations (eg, children, female or male specific, age limitations, illness populations). Studies were also excluded if they only presented the prevalence of consultations with other health professionals that may use treatments commonly associated with naturopathy (eg, herbal medicine, hydrotherapy, yoga) but were not explicitly named as naturopathic practitioners, or where naturopathic consultation rates were conflated with a cumulative group of health services (such as complementary and alternative medicine (CAM)). To ensure the analysis reflected contemporary patterns of use, studies were excluded if they were published before 2010.

**Search strategy**

A systematic electronic search of the following databases was conducted between 6 September 2019 and 2 October 2019: MEDLINE, AMED, EMBASE, CINAHL, Global Health, WHO Iris, PROQUEST dissertations database and Lilac. The complete search strategy for MEDLINE, using Medical Subject Headings (MeSH) terms where appropriate, is presented in box 2. A search for grey literature was also performed. The search targeted countries where, according to the WHO Global Report on Traditional and Complementary Medicine (2019),\textsuperscript{17} naturopathic practitioners provide care to the community. The search was performed using the Google search engine and the terms prevalence, use, naturopathy, report and the country name.

**Article identification and selection**

A list of all citations identified through the search were exported from each database by AM and uploaded to Covidence\textsuperscript{18} for filtering and selection. Initial screening of title and abstracts against the inclusion/exclusion criteria was conducted by AM. Two members of the authorship team (AM and AS) then independently reviewed the full text of the remaining citations to determine their suitability against the same criteria. Any differences were resolved through discussion between both reviewing authors. The list of bibliographic references and subsequent citations (identified through Google Scholar) of included papers were also checked by AS to identify additional articles otherwise missed through the database search. JEH and JS extracted data from the included papers. AS and JS assessed the papers for quality of reporting against the Strengthening the Reporting of Observational Studies in Epidemiology checklist\textsuperscript{19}, risk of bias was assessed using the tool developed by Hoy et al\textsuperscript{20} by JG and JA. Differences in scoring for both tools were resolved through discussion until consensus was achieved.

**Analysis**

The results were grouped for narrative presentation of results in accordance with the WHO world regions.\textsuperscript{21}

---

**Box 2  Example search terms applied to database searches**

1. Exp Complementary Therapies/
2. (Alternative or complementary or integrative) adj (medicine or therapy or therapies)).tw,kw.
3. Naturopathy/
5. Heilpraktiker.af.
6. 1 OR 2 OR 3 OR 4 OR 5
7. Cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ or cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab or retrospective.ti,ab.
8. Cross-Sectional Studies/ or Prevalence/ or (cross-sectional or prevalence or transversal).ti,ab,kw.
9. (Observational adj (study or studies)).tw.
10. Survey$tw.
11.7 OR 8 OR 9 OR 10
12. 6 AND 11
Where studies reported the results of more than one year, these were treated as different studies in the analysis. Articles with unclear numerators or denominators were calculated by the research team where the necessary information was provided or checked against source documents for the same study. Authors were contacted to verify information not able to be determined through these other methods.

Prevalence rates and standard errors were calculated using a standardised Microsoft Excel (V.12.3.5, Microsoft, Redmond, USA) spreadsheet. Review Manager software (V.5.3, Nordic Cochrane Centre, Copenhagen, Denmark) was used to conduct the meta-analysis, using random effects models by the generic inverse variance method. Weighted prevalence rates with 95% CI were calculated for 12-month prevalence and lifetime prevalence separately. Separate analyses were conducted for (1) country of origin and (2) WHO world regions.

Heterogeneity between studies was estimated on the basis of the raw proportions, by using the I^2 statistic. Intervals were defined as per published guidance: low heterogeneity (I^2 of 0%–24%); moderate heterogeneity (I^2 of 25%–49%); substantial heterogeneity (I^2 of 50%–74%); relevant heterogeneity (I^2 of 75%–100%). In order to assess heterogeneity, χ^2 tests were conducted with p≤0.10. We intended to perform sensitivity analyses to compare differences between outcomes on all studies to studies with low risk of bias only (defined as ≤4 items recorded as ‘no’ on the Hoy et al tool). However, as all studies were classified as low risk of bias, this was not possible.

RESULTS
Search characteristics
The article selection process is presented in figure 1. The database search identified 13 968 citations including 2509 duplicates. Of these, 11 374 were excluded through title and abstract screening. The full text of the remaining 85 articles were assessed for eligibility, of which 78 were excluded for the following reasons: not reporting naturopathic consultations (n=54), conference abstract only (n=9), not original research (n=7), wrong outcomes reported (n=5), overlooked duplicate (n=2) and wrong study design (n=1) (full list of excluded studies available in online supplemental file 1). This resulted in seven articles being retained. A search for grey literature using the Google Search engine was also performed, and targeted countries where, according to the WHO Global Report on Traditional and Complementary Medicine (2019), naturopaths/naturopathic doctors are providing care to the community. The reference lists and subsequent citations of the remaining articles were checked and when combined with the results of the Google Search, resulted in identification of an additional 19 articles (3 references and 16 citations), of which one report was found to meet the inclusion criteria for this review. This yielded a total

Figure 1 Flow chart representing article selection method in line with PRISMA protocol. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
of eight included studies, one of which was published in a report.

**Study characteristics**

The included studies reporting 12-month prevalence of naturopathy use in a national population were represented across four of the six WHO world regions: European (n=2),25,26 Eastern Mediterranean (n=1),27 Region of the Americas (n=3)28–30 and the Western Pacific (n=1)31 (see table 2). One of the studies from Canada presented the lifetime prevalence of naturopathy use,30 and an additional study from India (South East Asian World region) did not specify the time period during which naturopathy was used31 (see table 3).

All included studies sampled the general adult population and reported data from a nationally representative sample or demonstrated a distribution of economic categories, except for one study from Israel whereby the majority of participants’ subjective economic status was rated as ‘very good’ or ‘good’.27 Four studies included prevalence data from more than one time point,26–28,30 with the earliest data collected in 1993.27 Two papers reported data from the same national cohort study, but from different time points.28,29 All studies included participants from both urban and rural locations.

**Risk of bias**

Critical appraisal of the included studies is presented in table 4. All studies were determined to have a low risk of bias, except for one study that was suspected of having non-response bias.27 All but one study had problematic reporting of the numerator and denominator, however, this was able to be addressed by the research team by interrogating the provided data or checking source documents from the primary cohort studies. One study was identified as not having an acceptable case definition21 as it did not specify the period of time covering naturopathy use (eg, previous 12 months or users’ lifetime).

Assessment of the reporting quality of included studies identified several issues. More than one-half of studies did not clearly identify the study design in the title.21,27–31 None of the included studies provided reasons for non-participation or provided information about missing data. Four of the included studies did not acknowledge the limitations of their research. In one case, some of the omissions in reporting may be explained by the nature of the publication (ie, grey literature report rather than a peer-reviewed journal article).30

**Summary of findings**

The 12-month prevalence reported in studies from the European region ranged between 2% in the UK25 to 7.7% in Switzerland.36 One study from the Eastern Mediterranean region (ie, Israel)27 reported multiple prevalence rates ranging from 20% in 1993 through to 18% in 2007. Three studies from the Region of the Americas reported 12-month prevalence rates of naturopathy use between 3% (in 1997) and 5% (in 2016) in Canada,30 and between 0.25% (in 2002) and 0.4% (in 2015) in the USA.28,29 One study from the Western Pacific region (ie, Australia) reported a 6.2% prevalence rate.31

Two studies reported prevalence of naturopathy use over other time periods. One study from the Region of the Americas (Canada) indicated 6% of the general population in 1997, 9% in 2006, and 11% in 2016 used naturopathy at some point in the user’s lifetime.30 A study from the South-East Asian world region indicated 10% of the population had used naturopathy and yoga, but the time frame of use was not specified.32

**Meta-analysis results**

The estimated 12-month prevalence rates of naturopathy use for different countries are shown in figure 2. Prevalence rates significantly differed between countries (p<0.001) and ranged from less than 1% of the population in the USA to 8% in Switzerland. While the primary studies were subject to wide heterogeneity, significant heterogeneity was only found for Canada (p=0.01) and the USA (p<0.001).

Regarding WHO world regions, 12-month prevalence of naturopathy use ranged from 1% in the Region of the Americas to 6% in European and Western Pacific Regions, again with significant differences between regions (p<0.001; figure 3). Relevant and statistically significant heterogeneity was present in studies involving the European Region (p<0.001), and Region of the Americas (p<0.001).

Since all studies were classified as having low risk of bias, no sensitivity analyses were conducted. No meta-analysis could be performed on studies reporting prevalence of naturopathy use over other time periods due to the paucity and heterogeneity of studies reporting this outcome.

**DISCUSSION**

This review presents the most recent synthesis of evidence of the global prevalence of consultations with naturopaths/naturopathic doctors. The prevalence of naturopathy/naturopathic medicine use was reported in seven countries, across five WHO designated regions of the world. However, it should also be acknowledged that data were only available for a small number of countries in each world region. Intra-region variability limits the overall generalisability of such findings to the relevant region and, as such, aggregate regional results should be interpreted with caution. Of the regions reporting 12-month prevalence rates, the highest was in the Eastern Mediterranean region (Israel), with 18% (2007) to 20% (1993) of the general population seeking the services of a naturopath/naturopathic doctor. The lowest reported 12-month prevalence of naturopathy use was observed in the Americas (USA), with a rate of 0.4% (2012). Lifetime prevalence of use was reported in two countries: Canada (6% in 1997 to 11% in 2016); and India (7% rural, 12% urban in 2011/12). Where more than one timeframe of
### Table 2: Summary information of included studies reporting prevalence of use of naturopathy in the previous 12 months

<table>
<thead>
<tr>
<th>WHO region</th>
<th>Country (WHO region)</th>
<th>Author</th>
<th>Economic status</th>
<th>Design (measure)</th>
<th>Year data collected</th>
<th>Population</th>
<th>Naturopathy descriptor</th>
<th>Setting (eg, urban, rural)</th>
<th>N</th>
<th>Duration of exposure</th>
<th>Overall use (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>European</td>
<td>England</td>
<td>Hunt et al[16]</td>
<td>Nationally representative</td>
<td>National Cohort (survey)</td>
<td>2005</td>
<td>General population</td>
<td>Naturopathy</td>
<td>Both</td>
<td>7630</td>
<td>Previous 12 months</td>
<td>2*</td>
</tr>
<tr>
<td></td>
<td>Clarke et al[21]</td>
<td>Nationally representative</td>
<td>Cross-sectional survey (survey)</td>
<td>2012</td>
<td>General population</td>
<td>Naturopathy</td>
<td>National</td>
<td>38280</td>
<td>Previous 12 months</td>
<td>n=153; 0.4</td>
<td></td>
</tr>
<tr>
<td>Western Pacific</td>
<td>Australia</td>
<td>McIntyre et al[21]</td>
<td>Manageability on household income; impossible, difficult all/ some of time (58.6%), not too bad / easy (41.4%)</td>
<td>National Cross-sectional (survey)</td>
<td>2017</td>
<td>General population</td>
<td>Naturopathy and western herbal medicine</td>
<td>Both</td>
<td>2019</td>
<td>Previous 12 months</td>
<td>n=126; 6.2</td>
</tr>
</tbody>
</table>

*Estimated figure based on interpretation of the chart included in the article.
data was available, there was a relative amount of consistency across time suggesting naturopathy/naturopathic medicine use is temporally stable in these countries.

The wide range in the rates of consultation with a naturopath/naturopathic doctor may reflect differences in the perception and availability of naturopathy in specific countries. For example, while national prevalence of consultations with naturopaths in the USA is relatively low, this may obscure significant heterogeneity within that region. For example, insurance data from Washington state show prevalence of naturopathic consultation to be four times higher than the national prevalence (1.6% vs 0.4%). Such heterogeneity may be similarly observed in other regions and may be due to several factors. In the USA recognition of the naturopathic profession through licensure is not uniformly applied across that nation, and distribution of the naturopathic workforce has historically been determined by the proximity to naturopathic educational institutions.

Insurance coverage is also known to be a significant driver of naturopathic use, and variable insurance coverage arrangements for naturopathy—as observed in the USA—may also result in regional differences. Further attention towards regional variations and heterogeneity, particularly as it relates to specific barriers and facilitators to appropriate utilisation of naturopathic services—is warranted.

The wide range in rates of naturopathy use may also reflect differences in scope of practice in each world region. For example, in the USA, naturopathic physicians are considered to bridge conventional medicine and traditional medicine systems and treatments, while in Germany, naturopathic practitioners known as ‘Heilpraktiker’ are a distinct category and reportedly have inconsistent training and clinical abilities. As such, the term naturopathy may be differentially classifying practitioners due to professionalisation, resulting in an underestimate of use in some countries and overestimate in others. Further consideration of the implications associated with the inconsistent ‘protection’ of professional titles and defined scopes of practice for naturopaths/naturopathic doctors by country is likely to influence the prevalence of use by the public.

Prevalence data from some countries may also be impacted by definitional difficulties or confusion around the term ‘naturopathy’. For example, naturopathy is often grouped under a broader nomenclature as one of the many modalities or therapies considered ‘complementary approaches to healthcare’ or ‘integrative medicine’ and thus may not be individually represented in the publications included in our analysis. Multiple practitioner types may also present difficulties for data collection. For example, a review of complementary medicine services in Europe found that of the (22 300) practitioners of naturopathy, 15 000 were identified as (mostly German) medical doctors. Thus, patients may not identify obtaining naturopathy as a service per se, but as part of the standard care they receive from a medical doctor who integrates naturopathic principles or modalities into...
Table 4  Assessment of risk of bias and reporting quality for included studies

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Manuscript</th>
<th>Hunt et al.</th>
<th>Klein et al.</th>
<th>Shmueli et al.</th>
<th>Esmail</th>
<th>Su and Li</th>
<th>Clarke et al.</th>
<th>McIntyre et al.</th>
<th>Srinivasan and Sugumar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of bias</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>1—Representativeness of target population</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>2—Representativeness of sample population</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>3—Random selection or census</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>4—Non-response bias minimal</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>5—Data direct from participants</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>6—Acceptable case definition</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>7—Reliability and validity of instrument</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>8—Same mode of data for all subjects</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>9—Appropriate length of shortest prevalence period</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>10—Numerator and denominator appropriate</td>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>11—Summary</td>
<td></td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Reporting quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title and abstract</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>1a—Title</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>1b—Abstract</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Introduction</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>2—Background/rationale</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>3—Objectives</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Methods</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4—Study design</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>5—Setting</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>6—Participants</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>7—Variables</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>8—Data sources/measurement</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>9—Bias</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>10—Study size</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>11—Quantitative variables</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>12a—All statistical methods</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>12b—Subgroups and interactions</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>12c—Missing data</td>
<td></td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>12d—Analysis accounting for sampling</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>12e—Any sensitivity analysis</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Results</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13a—Numbers of participants</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>13b—Reasons for nonparticipation</td>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>13c—Flow diagram</td>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>14a—Characteristics of study participants</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>14b—Participants with missing data</td>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>15—Outcome data</td>
<td></td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>16a—Unadjusted and applicable adjusted estimates</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>16b—Report category boundaries</td>
<td></td>
<td>?</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>N/A</td>
<td>Y</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>16c—Estimates of absolute risk</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>17—Other analyses</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18—Key results</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>19—Limitations</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>20—Interpretation</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
</tbody>
</table>

Continued
their practice. This may be one reason why three of the largest European countries by naturopathic workforce (Germany, Portugal and Spain) were not represented in this review. Thus, the true prevalence of naturopathic consultations is likely under-reported. Further, an examination of government administered national health surveys of the general population in the countries represented by World Naturopathic Federation (WNF) member organisations, found only Switzerland, Northern Ireland, USA, Mexico and India currently included items that specifically measured consultations with a naturopath/naturopathic doctor (see online supplemental file 2 and figure 4). While some non-government research has undertaken to measure the prevalence of naturopathy use in additional countries, data are not available in more than 90% of countries with WNF member organisations, and 95% of all countries reported by the WHO as having a naturopathic profession. To evaluate the potential role of naturopaths in care delivery, it is imperative that naturopathic health services and workforce research data is captured in all countries where there is a significant naturopathic presence.

Furthermore, although naturopathic practice is relatively consistent globally, local, and regional variations in preferred therapies may result in point-of-service differences that may impact prevalence of naturopathic use.

Table 4 Continued

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Manuscript</th>
<th>Klein et al</th>
<th>Shmueli et al</th>
<th>Esmai1</th>
<th>Su and Li2</th>
<th>Clarke et al3</th>
<th>McIntyre et al4</th>
<th>Srinivasan and Sugumar5</th>
</tr>
</thead>
</table>

Study or Subgroup | 12-month prevalence | SE | Weight | Test for overall effect: Z = 11.22 (P < 0.0001) |
--- | --- | --- | --- | --- |
1.1.1 Australia | | | | |
McIntyre 2019 | 0.06240713 | 0.00555967 | 100.0% | 0.06 [0.05, 0.07] |
Subtotal (95% CI) | 100.0% | 0.06 [0.05, 0.07] |
Heterogeneity: Not applicable |
Test for overall effect: Z = 11.22 (P < 0.0001) |
1.1.2 Canada | | | | |
Esmai 1997 | 0.03 | 0.0044721 | 33.9% | 0.03 [0.02, 0.04] |
Esmai 2006 | 0.04 | 0.0044721 | 33.9% | 0.04 [0.03, 0.05] |
Esmai 2016 | 0.05 | 0.005 | 32.2% | 0.05 [0.04, 0.06] |
Subtotal (95% CI) | 100.0% | 0.04 [0.03, 0.05] |
Heterogeneity: Tau² = 0.00; CH² = 8.93, df = 2 (P = 0.01); I² = 78% |
Test for overall effect: Z = 7.03 (P < 0.0001) |
1.1.3 England | | | | |
Hunt 2010 | 0.02005242 | 0.00162114 | 100.0% | 0.02 [0.02, 0.02] |
Subtotal (95% CI) | 100.0% | 0.02 [0.02, 0.02] |
Heterogeneity: Not applicable |
Test for overall effect: Z = 12.37 (P < 0.0001) |
1.1.4 Israel | | | | |
Shmueli 1993 | 0.1997004 | 0.0099685 | 35.7% | 0.20 [0.18, 0.22] |
Shmueli 2000 | 0.1606607 | 0.0082208 | 40.0% | 0.17 [0.15, 0.19] |
Shmueli 2007 | 0.1795213 | 0.0154507 | 24.3% | 0.18 [0.15, 0.21] |
Subtotal (95% CI) | 100.0% | 0.18 [0.16, 0.20] |
Heterogeneity: Tau² = 0.00; CH² = 5.41, df = 2 (P = 0.07); I² = 63% |
Test for overall effect: Z = 17.79 (P < 0.0001) |
1.1.5 Switzerland | | | | |
Klein 2007 | 0.0821052 | 0.0023852 | 48.0% | 0.08 [0.08, 0.09] |
Klein 2012 | 0.0669679 | 0.0021769 | 52.0% | 0.09 [0.08, 0.09] |
Subtotal (95% CI) | 100.0% | 0.08 [0.08, 0.09] |
Heterogeneity: Tau² = 0.00; CH² = 2.29, df = 1 (P = 0.13); I² = 56% |
Test for overall effect: Z = 34.67 (P < 0.00001) |
1.1.6 USA | | | | |
Clarke 2015 | 0.0039969 | 0.0003230 | 33.9% | 0.00 [0.00, 0.00] |
Su 2007 | 0.0025109 | 0.0002860 | 35.0% | 0.00 [0.00, 0.00] |
Su 2007 | 0.00341856 | 0.00040571 | 31.1% | 0.00 [0.00, 0.00] |
Subtotal (95% CI) | 100.0% | 0.00 [0.00, 0.00] |
Heterogeneity: Tau² = 0.00; CH² = 12.08, df = 2 (P = 0.002); I² = 83% |
Test for overall effect: Z = 6.92 (P < 0.00001) |

Test for subgroup differences: CH² = 1554.47, df = 5 (P < 0.00001); I² = 99.7% |

Figure 2 A 12-month prevalence of naturopathy use in different countries. IV, inverse variance.
consultations in those countries. For example, in the UK, historical connections between osteopathy and naturopathy may drive naturopathic use for musculoskeletal conditions in that country more than in countries like Australia, where naturopathy and herbalism have had a larger shared history and connection.41 Some studies in this review explicitly combined queries about naturopathic utilisation with other complementary medicine practices—for example, herbalism and naturopathy in the Australian study. Thus, it is important that a reliable validated instrument is developed for collecting more specific data about naturopathic service utilisation within and across countries to establish ‘true’ prevalence of use information.

While prevalence data provides a snapshot of a given populations’ use of naturopathy, less is known about the factors associated with that use. For example, factors that have previously been raised as impacting the use of naturopathy/naturopathic medicine, include licence and regulation, scope of practice, training of new

Figure 3  A 12-month prevalence of naturopathy use in different world regions. IV, inverse variance.

Figure 4  Availability of national data reporting prevalence of consultations with a naturopathic practitioner, by countries with World Naturopathic Federation (WNF) member organisations or institutions. (0=absent from national survey, 1=present but aggregated with at least one other health profession, 2=present as separate health profession; non-member countries are depicted in the lightest colour).
students and therefore number of naturopaths/naturopathic doctors in the workforce, or country specific health systems that influence the support and reimbursements of naturopathic services (e.g., insurance vs out of pocket). By focusing on general population utilisation, this study may also not reflect differences in prevalence of use for different clinical conditions. For example, Australian studies published before 2010 show a self-reported prevalence of naturopathic use among the general population of mid-aged women to be 8.7%, while rates of use for cancer (15.7%) and depression (22.2%) were significantly higher. Similar variations were seen in insurance data from Washington state in the USA, where 7.1% of insured cancer patients made claims for naturopathic treatment, compared with 1.6% of general enrollees. With this in mind, future research should more closely examine the characteristics of users of naturopathy in different countries and world regions both for the general population and within subpopulations.

One of the limitations of prevalence studies in the context of naturopathy, is they fail to capture the breadth of treatments that is unique to naturopathy and they do not capture data associated with the quality of care, role within healthcare systems, nor the efficacy and safety of naturopathic approaches to the management of specific conditions. Thus, research into the quality, safety, efficacy and cost-effectiveness of naturopathy/naturopathic medicine would provide pragmatic understanding about the contribution of naturopathy to healthcare within populations and more broadly across the world. Additionally, although limiting data collection to studies published after 2010 helps to ensure prevalence data most accurately reflects contemporary utilisation, such time limits may have excluded some studies in regions that were missing from the review. Additionally, observing changes in prevalence of naturopathic consultations over time may also be able to offer insights into the changing role of naturopathy/naturopathic medicine in relation to health systems changes or generational health needs.

CONCLUSION

Although the naturopathic workforce has a significant presence globally, there is limited detailed data on the prevalence of naturopathic consultations. As such, there is a need for a reliable validated instrument to be developed for collecting more specific data about naturopathic service utilisation within and across countries. Nevertheless, current evidence reports a 12-month prevalence of naturopathy use ranging from 1% in the Region of the Americas to 6% in European and Western Pacific Regions, though there are significant differences between and within world regions. Differences in naturopathic utilisation in these regions may be indicative of a range of policy, legislative and social factors impacting the naturopathic profession. Despite these ongoing factors, further research attention is warranted to develop evidence-based responses to the WHO recommendation that naturopathy and other traditional medicines be integrated, where appropriate, into healthcare systems so that consumers have access to safe and effective multidisciplinary care.

Author affiliations
1Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), University of Technology Sydney, Sydney, New South Wales, Australia
2National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia
3Department of Internal and Integrative Medicine, Klinikken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Duisburg, Germany
4Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, USA
5School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
6University of Tasmania, Hobart, Tasmania, Australia
7Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada
8University of Lethbridge, Lethbridge, Alberta, Canada

Twitter Matthew J Leach @DrMatthewLeach

Contributors AS devised the project, the main conceptual idea and drafted the review protocol and is guarantor for the manuscript. All authors reviewed and edited the protocol prior to registration. Literature searching, removal of duplicates and filtering of citations by title and abstract was undertaken by AM. Full text retrieval and assessment of articles against eligibility criteria was undertaken by AM and AS. Data extraction was completed by JEH. STROBE assessment was completed by CVW, JS and AS. Risk of bias assessment was completed by JG, JH and AS. Meta-analysis was completed by JG, KC and HC. The method section of the manuscript was drafted by HC, AS, JS and JH. The results were drafted by AS and HC. The discussion was drafted by JEH, JN, JA and BL. The introduction was drafted by RR, MJL and RB. All authors reviewed and edited the full draft of the manuscript prior to submission.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval As this study presents a review and synthesis of published research and does not engage with data collection of human or animal subjects, it is deemed negligible risk and no ethics approval was required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Amie Steel http://orcid.org/0000-0001-6643-9444
Joanna Elizabeth Harnett http://orcid.org/0000-0001-9904-2144
Kieran Cooley http://orcid.org/0000-0001-7960-6504

REFERENCES

8 Leach MJ. Profile of the complementary and alternative medicine workforce across Australia, New Zealand, Canada, United States and United Kingdom. Complement Ther Med 2013;21:364–78.
18 Innovation VH. Covidence systematic review software. Melbourne, Australia.
30 Esmail N. Complementary and alternative medicine. Fraser Institute, 2017.